Evidence map›Paper›PMID 29018056›Full record

ArticleMolecular cancer research : MCR2018

Functional Genomics Approach Identifies Novel Signaling Regulators of TGFα Ectodomain Shedding.

Jennifer L Wilson, Eirini Kefaloyianni, Lauren Stopfer, Christina Harrison, Venkata S Sabbisetti, Ernest Fraenkel, Douglas A Lauffenburger, Andreas Herrlich

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jennifer L WilsonDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Eirini KefaloyianniDivision of Nephrology, Washington University School of Medicine, St. Louis, Missouri.
Lauren StopferDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Christina HarrisonDepartment of Biology, University of Massachusetts, Boston, Massachusetts.
Venkata S SabbisettiRenal Division, Brigham and Women's Hospital, Boston, Massachusetts.
Ernest FraenkelDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts. aherrlich@wustl.edu lauffen@mit.edu.
Andreas HerrlichDivision of Nephrology, Washington University School of Medicine, St. Louis, Missouri. aherrlich@wustl.edu lauffen@mit.edu.
Massachusetts Institute of Technology · USWashington University in St. Louis · USBrigham and Women's Hospital · USUniversity of Massachusetts Boston · US

Funding

TRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024
$13.1M
Engineered Antibody EGFR Antagonist Cancer TherapeuticsR01CA096504 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WITTRUP, KARL DANE · 2002 to 2017
$9.7M
Embryonal Brain Tumor NetworksU01CA184898 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FRAENKEL, ERNEST, MESIROV, JILL P. · 2014 to 2019
$3.6M
Analysis of the Signaling and Mechanical Cues Promoting Invasion in MelanomaU01CA155758 · NCI · YALE UNIVERSITY · PI LAUFFENBURGER, DOUGLAS A, LEVCHENKO, ANDRE · 2011 to 2015
$1.8M
Role of ADAM17 substrates in Progressive Kidney DiseaseR01DK108947 · NIDDK · WASHINGTON UNIVERSITY · PI HERRLICH, ANDREAS · 2016 to 2019
$1.4M
Identification of novel genes regulating metalloproteinase activityR00DK077731 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI HERRLICH, ANDREAS · 2010 to 2012
$738k
NCI NIH HHS R01 CA096504NCI NIH HHS U01 CA155758NCI NIH HHS U01 CA184898NIDDK NIH HHS R00 DK077731NIDDK NIH HHS R01 DK108947
6 · The paper itself

Abstract

Ectodomain shedding of cell-surface precursor proteins by metalloproteases generates important cellular signaling molecules. Of importance for disease is the release of ligands that activate the EGFR, such as TGFα, which is mostly carried out by ADAM17 [a member of the A-disintegrin and metalloprotease (ADAM) domain family]. EGFR ligand shedding has been linked to many diseases, in particular cancer development, growth and metastasis, as well as resistance to cancer therapeutics. Excessive EGFR ligand release can outcompete therapeutic EGFR inhibition or the inhibition of other growth factor pathways by providing bypass signaling via EGFR activation. Drugging metalloproteases directly have failed clinically because it indiscriminately affected shedding of numerous substrates. It is therefore essential to identify regulators for EGFR ligand cleavage. Here, integration of a functional shRNA genomic screen, computational network analysis, and dedicated validation tests succeeded in identifying several key signaling pathways as novel regulators of TGFα shedding in cancer cells. Most notably, a cluster of genes with NFκB pathway regulatory functions was found to strongly influence TGFα release, albeit independent of their NFκB regulatory functions. Inflammatory regulators thus also govern cancer cell growth-promoting ectodomain cleavage, lending mechanistic understanding to the well-known connection between inflammation and cancer.

Indexed as

Cell Line, TumorErbB ReceptorsGene Regulatory NetworksGenomicsHumansJurkat CellsLigandsModels, GeneticNeoplasmsRNA, Small InterferingSignal TransductionTransforming Growth Factor alphaEGFR protein, humanErbB ReceptorsLigandsRNA, Small InterferingTransforming Growth Factor alpha

Identifiers

PMID29018056
PMCPMC5859574
OpenAlexW2761767525

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.